← Back
NeuroTrials.ai
Neurology Clinical Trial Database

TEMPO-2

Tenecteplase Versus Standard of Care for Minor Ischaemic Stroke With Proven Occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial

Year of Publication: 2024

Authors: Shelagh B. Coutts, Sandeep Ankolekar, Ramana Appireddy, ..., Michael D. Hill

Journal: Lancet

Citation: Lancet 2024; 401(10444): 2597-2605


Clinical Question

Is intravenous tenecteplase (0.25mg/kg) superior to non-thrombolytic standard of care in preventing disability at 90 days in patients with minor ischaemic stroke (NIHSS ≤5) and intracranial occlusion presenting within 12 hours of onset?

Bottom Line

Tenecteplase did not improve functional outcomes compared to standard care in minor stroke patients with intracranial occlusion, and was associated with increased mortality. Patients with minor stroke and intracranial occlusion should not be routinely treated with intravenous thrombolysis.

Major Points

  • Trial stopped early for futility after planned interim analysis (conditional power <1%)
  • No difference in primary outcome: return to baseline mRS 71.5% tenecteplase vs 74.8% control (RR 0.96, 95% CI 0.88-1.04)
  • Higher 90-day mortality in tenecteplase group: 4.6% vs 1.1% (adjHR 3.8, 95% CI 1.4-10.2, p=0.009)
  • Trend toward more symptomatic ICH with tenecteplase: 1.9% vs 0.4% (RR 4.2, p=0.059)
  • Higher early recanalization with tenecteplase (47.7% vs 21.6%) but no functional benefit
  • More patients achieved NIHSS 0 at discharge with tenecteplase (57.8% vs 50%), but no 90-day benefit
  • Control group predominantly received dual antiplatelet therapy (57.3%)
  • Subgroup analyses suggested women and patients >80 years may fare worse with tenecteplase

Design

Study Type: Randomised, open-label with blinded endpoint assessment (PROBE), parallel group, phase 3 superiority trial

Randomization: 1

Blinding: Open-label treatment allocation with blinded outcome assessment at 90 days by certified raters

Enrollment Period: April 27, 2015 to January 19, 2024

Follow-up Duration: 90 days (median 92 days, IQR 85-99)

Centers: 48

Countries: Canada, Australia, United Kingdom, Singapore, Brazil, New Zealand, Finland, Austria, Spain, Ireland

Sample Size: 884

Analysis: Intention-to-treat analysis. Generalized linear modelling with Poisson distribution and log link function to generate risk ratios. Robust (Huber-Sandwich) standard error estimation. Cox proportional hazards model for mortality. Minimal sufficient balance randomisation algorithm.


Inclusion Criteria

  • Age ≥18 years
  • Functionally independent before stroke (baseline pre-stroke mRS 0-2)
  • Minor stroke with NIHSS score ≤5
  • Presented within 12 hours of last seen normal
  • Direct imaging evidence of intracranial occlusion or indirect evidence with focal perfusion lesion relevant to presenting symptoms
  • No region of well-evolved infarction concordant with acute presenting syndrome
  • ASPECTS score ≥7
  • Patient and physician judged that routine IV thrombolysis was not warranted

Exclusion Criteria

  • Standard contraindications to intravenous thrombolysis

Arms

FieldTenecteplaseControl
InterventionTenecteplase 0.25mg/kg (maximum dose 50mg) as a single intravenous bolus administered over 5-10 seconds immediately after randomisationStandard of care non-thrombolytic treatment; at minimum single agent antiplatelet therapy. Guideline-based care recommended with local investigator choice of antithrombotic regimen. Majority received dual antiplatelet therapy with aspirin and clopidogrel (57.3%) or aspirin monotherapy (23.5%)
DurationSingle bolusPer clinical judgment

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Return to baseline neurological functioning measured by mRS using sliding dichotomy approach. Responder defined as: If pre-morbid mRS 0-1, then mRS 0-1 at 90 days; if pre-morbid mRS 2, then mRS 0-2 at 90 daysPrimary338/452 (74.8%)309/432 (71.5%)0.2882
mRS 0-1 at 90 daysSecondary321/452 (71.3%)298/432 (69.0%)RR 0.97
mRS 0-2 at 90 days (functional independence)Secondary391/452 (86.9%)352/432 (81.5%)RR 0.94
NIHSS = 0 at 5 days or dischargeSecondary226/452 (50.0%)247/432 (57.8%)RR 1.16
Return to pre-morbid mRSSecondary222/452 (49.1%)212/432 (49.1%)RR 1.00
Mean mRS score at 90 daysSecondary1.111.27Difference 0.16
Median mRS at 90 daysSecondary1 (IQR 0-2)1 (IQR 0-2)
Lawton IADL percent functioningSecondary90.8%86.4%Difference -4.5
EQ5D-5L indexSecondary0.840.81Difference -0.03
EQ5D-5L VASSecondary0.760.73Difference -3.4
Recanalization at 4-8 hours (subset n=515)Secondary21.6%47.7%<0.001
Death at 90 daysAdverse5/452 (1.1%)20/432 (4.6%)adjHR 3.80.0085
Death within 5 daysAdverse1/452 (0.2%)8/432 (1.9%)0.0184
Symptomatic ICHAdverse2/452 (0.4%)8/432 (1.9%)RR 4.20.0588
Death after symptomatic ICHAdverse1/452 (0.2%)6/432 (1.4%)1.0000
Any hemorrhage on follow-up imagingAdverse40/452 (9.2%)62/432 (14.4%)0.0202
SAE occurredAdverse80/452 (17.7%)100/432 (23.1%)0.0454
Stroke progressionAdverse33/452 (7.3%)35/432 (8.1%)0.7056
Stroke recurrenceAdverse15/452 (3.3%)16/432 (3.7%)0.8554
Rescue EVT for index strokeAdverse10/452 (2.2%)15/432 (3.5%)0.3120
Aspiration pneumoniaAdverse2/452 (0.4%)6/432 (1.4%)0.1688
Atrial fibrillationAdverse3/452 (0.7%)4/432 (0.9%)0.7198
Congestive Heart FailureAdverse1/452 (0.2%)5/432 (1.2%)0.1159
SeizureAdverse3/452 (0.7%)3/432 (0.7%)1.0000
Urinary Tract InfectionAdverse4/452 (0.9%)2/432 (0.5%)0.6869

Subgroup Analysis

Heterogeneity of treatment effect suggested by sex (p_int=0.043): women more likely to do better with control (risk difference 10.1%) vs men (no effect). Age interaction (p_int=0.038): patients >80 years more likely to do better with control (risk difference 14.9%) vs younger patients (no effect). No heterogeneity by onset to treatment time (≤4.5h vs >4.5h), symptom status, occlusion type (LVO vs MeVO vs VB vs perfusion lesion), or baseline NIHSS.


Criticisms

  • Open-label treatment allocation (though outcome assessment was blinded)
  • Trial took nearly 9 years to complete due to pandemic and drug supply issues, with potential for selection bias and secular changes in care
  • Control group treatment was heterogeneous (not one single comparator), though this may improve generalizability
  • Patients with focal perfusion lesion (without overt occlusion) may be qualitatively different from those with visible arterial occlusion
  • Excess late deaths in tenecteplase group remain unexplained and may be chance finding given low absolute numbers
  • No parallel registry collected to confirm that enrolled patients did not have disabling symptoms
  • 149/884 (17%) had complete symptom resolution at randomization
  • Higher recanalization rate (47.7%) may not have been sufficient to influence outcomes

Funding

Heart and Stroke Foundation of Canada, Canadian Institutes of Health Research, British Heart Foundation. Tenecteplase was standard off-the-shelf drug paid for by Boehringer Ingelheim (no role in trial design, conduct, data analysis, or manuscript preparation)

Based on: TEMPO-2 (Lancet, 2024)

Authors: Shelagh B. Coutts, Sandeep Ankolekar, Ramana Appireddy, ..., Michael D. Hill

Citation: Lancet 2024; 401(10444): 2597-2605

Content summarized and formatted by NeuroTrials.ai.